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Here, we describe a serological enzyme-linked immunosor-
bent assay for the screening and identification of human 
SARS-CoV-2 seroconverters. This assay does not require the 
handling of infectious virus, can be adjusted to detect differ-
ent antibody types in serum and plasma and is amenable to 
scaling. Serological assays are of critical importance to help 
define previous exposure to SARS-CoV-2 in populations, iden-
tify highly reactive human donors for convalescent plasma 
therapy and investigate correlates of protection.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)— 
a member of the subgenus Sarbecovirus—has spread globally, 
causing a pandemic with, so far, 3.6 million infections and 250,000 
fatalities (as of 5 May 2020).
Nucleic acid tests that detect the SARS-CoV-2 RNA genome 
are now widely employed to diagnose coronavirus disease 2019 
(COVID-19). However, there remains a great need for assays 
that measure antibody responses and determine seroconversion. 
While such serological assays are not well suited to detect acute 
infections, they support a number of highly relevant applications. 
First, serological assays allow us to study the immune response(s) 
to SARS-CoV-2 in a qualitative and quantitative manner. Second, 
serosurveys are needed to determine the precise rate of infection in 
an affected area, which is an essential variable to accurately deter-
mine the infection fatality rate. Third, serological assays will allow 
for the identification of individuals who mounted strong antibody 
responses and who could serve as donors for the generation of 
convalescent serum/plasma therapeutics. Lastly, serological assays 
can help inform studies that aim to identify antibody responses that 
correlate with protection from SARS-CoV-2.
Sarbecoviruses express a large (approximately 140 kDa) glycopro-
tein termed spike protein (S, a homotrimer), which mediates bind-
ing to host cells via interactions with the human receptor angiotensin 
converting enzyme 2 (ACE2)1–3. The S protein is highly immuno-
genic with the receptor-binding domain (RBD) being the target of 
many neutralizing antibodies4. Individuals infected with coronavi-
ruses typically mount neutralizing antibodies5 and a neutralizing 
response has been demonstrated for SARS-CoV-2 in an individual 
case from day 9 onwards6. For human coronaviruses these responses 
have been linked to protection for a period of time and future stud-
ies will show if there is a correlation between neutralizing antibodies 
and protection from SARS-CoV-2 infection as well5. Serum neutral-
ization can be measured using replication competent virus but the 
process requires several days and must be conducted in a biosafety 
level 3 laboratory for containment of SARS-CoV-2. Potentially, 
pseudotyped viral particle based entry assays using lentiviruses or 
vesicular stomatitis virus could be used but these reagents are not 
trivial to produce. A simple solution is the use of a binding assay, 
e.g. an enzyme-linked immunosorbent assays (ELISA), with recom-
binant antigen as substrate, especially if ELISA results correlate with 
neutralization assay results. Here we report the development of 
such an assay and provide a protocol for both recombinant antigen 
production as well as the ELISA methodology7.
We generated two different versions of the SARS-CoV-2 spike 
protein, based on the genomic sequence of the first virus isolate, 
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Wuhan-Hu-1 (ref. 8). The first construct encodes a full-length tri-
meric and stabilized version of the spike protein, whereas the second 
produces only the much smaller RBD. Sequences were codon opti-
mized for mammalian cell expression. The full-length spike protein 
sequence was modified to remove the polybasic cleavage site, which 
is recognized by furin, and to add a pair of stabilizing mutations 
(Extended Data Fig. 1)2,9,10. These two modifications were included 
to enhance the stability of the protein based on published litera-
ture2,9. At amino acid P1213, the sequence was fused to a thrombin 
cleavage site, a T4 foldon sequence for proper trimerization and a 
carboxy (C)-terminal hexahistidine tag for purification (Extended 
Data Fig. 1). The sequence was cloned into a pCAGGS vector 
for expression in mammalian cells and into a modified pFastBac 
Dual vector for the generation of baculoviruses and expression in 
insect cells. For expression of the RBD, the natural amino-terminal 
signal peptide of S was fused to the RBD sequence (amino acids 
319–541) and joined with a C-terminal hexahistidine tag11. The 
same vectors as for the full-length S protein were used to express 
the RBD. In mammalian cells (Expi293F), the RBD domain gave 
high yields (approximately 25–50 mg l−1 of culture), but expression 
was lower in insect cells (approximately 1.5 mg l−1 of culture). Clear 
single bands were visible when the recombinant RBD proteins were 
analyzed by reducing sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE), with the insect cell-derived protein 
(iRBD) running slightly lower than the mammalian cell-derived 
protein (mRBD) (Extended Data Fig. 1). The size difference prob-
ably reflects differences in glycan sizes between insect cells and 
mammalian cells. The full-length S protein was also expressed in 
both systems with higher yields in mammalian cells (mSpike) than 
in insect cells (iSpike) (~5 versus ~0.5 mg l−1 of culture). Reducing 
SDS-PAGE showed the full-length protein as a prominent band 
between 135 and 190 kDa, followed by a faint second band slightly 
below, which may be a cleavage product.
ELISAs were performed by serial dilution of the individual 
serum samples. Values from the dilution curves were used to deter-
mine the area under the curve (AUC), which was plotted on a graph. 
Initially, we tested a panel of 50 (59 for mRBD) banked human 
serum samples collected from study participants with and with-
out confirmed previous viral infections (but otherwise healthy), to 
establish an ELISA with our proteins. These human sera were used 
to test the background reactivity to the SARS-CoV-2 spike in sam-
ples representative of the general US population from individuals 
ranging from 20 to ≥65 years. An initial set of four plasma/serum 
samples from three COVID-19 survivors were used to determine 
the reactivity of SARS-CoV-2-infected individuals to the RBD and 
the full-length spike (Fig. 1).
All COVID-19 plasma/serum samples reacted strongly to 
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Fig. 1 | Reactivity of control and SARS-CoV-2 convalescent sera to different spike antigens. a–d, Reactivity to iRBD (a), mRBD (b), iSpike (c) and mSpike (d).  
Red, green and black data points/lines show the results for sera from SARS-CoV-2-infected individuals, a convalescent serum sample post-NL63 infection and 
other negative control samples, respectively. e–h, Data from the same experiment as in a–d, respectively, but plotted as AUCs to obtain a better quantitative 
impression (control samples: n = 50 for iRDB, iSpike and mSpike; n = 59 for mRBD; convalescent samples: n = 4 for iRBD and iSpike; n = 16 for mRBD and 
mSpike). Statistical analyses were performed using an unpaired two-tailed Student’s t-test in GraphPad Prism. Horizontal lines represent mean values.  
i,j, Reactivity of the 50 negative control samples from a–h against spike protein from human coronaviruses 229E (i) and NL63 (j). k, Correlation between 
ELISA titers and microneutralization titers (n = 12; the three samples from negative control sera overlap and are displayed as a single point). Statistical analysis 
was performed using Pearson’s rank test in GraphPad Prism. The experiments were performed once. IC50, half-maximum inhibitory concentration.
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other serum samples only yielded background reactivity (Fig. 1). 
Reactivity of COVID-19 sera was, in general, stronger against the 
full-length S protein than against the RBD, both for raw optical 
density and AUC values, which may reflect the higher number of 
epitopes found on the much larger spike protein. For the RBD, the 
difference between control sera and convalescent samples (initial 
n = 4) was larger when the mRBD was used compared with the 
iRBD. The same was true for the full-length spike protein. We tested 
an additional 12 serum samples from patients with acute COVID-
19 disease, as well as convalescent participants, for reactivity to 
mRBD and mSpike (Fig. 1). All 12 samples reacted with both RBD 
and spike protein. Thus, our assay distinguished sera from par-
ticipants diagnosed with COVID-19 from serum samples collected 
before the pandemic (for example, collected in the autumn of 2019).
Our initial set of negative controls included convalescent serum 
from a participant with a confirmed NL63 infection. Importantly, 
this sample did not produce a signal against the SARS-CoV-2 RBD 
or spike. Since human coronaviruses OC43, 229E, NL63 and/or 
HKU1 are responsible for a large proportion of common colds every 
year, cross-reactivity between SARS-CoV-2 and these seasonal coro-
naviruses is of particular importance and warrants further investi-
gation. To test how common antibodies to human coronaviruses 
other than SARS-CoV-2 are in our pre-pandemic serum panel, 
we performed ELISAs coated with spike protein of coronaviruses 
229E and NL63. While none of the negative control sera reacted to 
SARS-CoV-2 RBD and spike, the majority of samples yielded strong 
signals to the spike proteins of these two human coronaviruses 
(Fig. 1i,j). In addition, we tested 21 different batches (27 vials) of 
pools of different products of normal human immune globulin 
(NHIG) that were intended for intravenous use and derived from 
>1,000 donors each. None of the NHIG preparations reacted with 
SARS-CoV-2 RBD or spike protein and the signal obtained was sim-
ilar to that of the three irrelevant human monoclonal antibodies. In 
contrast, the RBD-binding monoclonal antibody CR3022 produced 
a strong signal in the ELISA (Extended Data Fig. 2a,b)12–14. Lastly, 
we tested a panel of 50 plasma samples collected from patients posi-
tive for human immunodeficiency virus and banked from 2008 and 
2011. Again, none of the samples reacted with the SARS-CoV-2 
RBD or spike (Extended Data Fig. 2c,d).
For the plasma/sera of patients with COVID-19 from our ini-
tial panel, we performed an isotyping and subtyping ELISA using 
the mammalian cell-expressed S proteins. Strong reactivity was 
found for all samples for immunoglobulin G3 (IgG3), IgM and 
IgA (Extended Data Fig. 3a). An IgG1 signal was detected for the 
majority of samples, in addition to low reactivity for IgG2 (in five of 
the COVID-19 samples) and IgG4 (in four samples). Furthermore, 
we correlated the ELISA reactivity with the neutralizing activity 
of sera against the USA-WA1/2020 isolate. ELISA titers and micro-
neutralization titers correlated significantly (Fig. 1k and Extended 
Data Fig. 3b), with a Spearman’s r of 0.9279 (P < 0.0001).
One complexity with measuring antibodies in the bodily fluids 
of patients with COVID-19 is that infectious virus could be pres-
ent in the biospecimen. To limit this risk, serum or plasma is heat 
inactivated for 1 h at 56 °C. To test whether such a heat treatment 
has an effect on detecting antibodies to the SARS-CoV-2 RBD 
and spike, we compared the reactivity of matched non-treated and 
heat-treated serum samples from patients with COVID-19. While 
slight differences were observed, they were minimal, suggesting that 
heat treatment may have no negative impact on assay performance 
(Fig. 2a,b). Similarly, we tested matched serum and plasma samples 
from patients with COVID-19 and found negligible differences, 
suggesting that both types of specimens can be used in the assay 
interchangeably (Fig. 2c,d).
Here, we describe a serological method to detect seroconver-
sion upon SARS-CoV-2 infection. The method is based on reactiv-
ity to the immunogenic S protein of the virus, is relatively simple 
and quick in its execution and can be performed at biosafety level 2 
as it does not involve live virus. We have tested this method using 
banked serum samples and NHIG preparations obtained from 
individuals before SARS-CoV-2 started to widely circulate in the 
United States. These serum samples produced low, close-to-baseline 
signals in our ELISAs. The age of the participants ranged from 20 
to ≥65 years of age and it is likely that most of these individuals 
had experienced infections with human coronaviruses, including 
the alphacoronaviruses NL63 and 229E, as well as the betacoronavi-
ruses OC43 and HKU1 (ref. 5). In fact, the majority of our negative 
control subjects had strong reactivity to the spike protein of NL63 
and 229E, but showed no cross-reactivity to SARS-CoV-2 RBD and 
spike. We also included a convalescent serum sample from a partici-
pant with a laboratory-confirmed coronavirus NL63 infection. Our 
data show that there is no or only negligible cross-reactivity from 
human coronaviruses to SARS-CoV-2 in these individuals. Similar 
findings were reported in a recent study where sera from negative 
control subjects reacted well with spike proteins from human coro-
navirus but not with SARS-CoV-2 (ref. 15). This is notable because 
it suggests that humans are serologically naive to SARS-CoV-2, 
which may explain the relatively high basic reproduction num-
ber (or R0) of SARS-CoV-2 compared with that of other respira-
tory viruses, such as influenza virus16. As a caveat, the reactivity of 
samples from SARS-CoV-1- or Middle East respiratory syndrome 
coronavirus-infected individuals was not tested, and cross-reaction 
might occur in this assay. Another caveat is of course the relatively 
small number of samples tested.
Our data show strong seroconversion with ELISA AUC values 
in the 1:1,000 range after natural infection with SARS-CoV-2. 













































































Fig. 2 | Effect of heat treatment and serum versus plasma on assay 
performance. a,b, Reactivity of paired non-treated serum and heat-treated 
serum samples to mRBD (a) and mSpike (b) of SARS-CoV-2 (n = 5).  
c,d, Reactivity of paired serum and plasma samples to mRBD (c) and 
mSpike (d) of SARS-CoV-2 (n = 7). Statistical analyses were performed 
using a paired two-tailed Student’s t-test in GraphPad Prism. The experiments 
were performed once.
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infection target the full-length S protein as well as the RBD, which 
is the major target for neutralizing antibodies for related corona-
viruses4. In fact, one of the SARS-CoV-2 samples was previously 
tested in another study in neutralization assays and showed a neu-
tralizing titer of 1:160 (ref. 6). In addition, we performed microneu-
tralization assays with a subset of our samples and found excellent 
correlation between our ELISA titers against the spike protein and 
virus neutralization, with several samples showing strong neutraliz-
ing activity with 50% inhibitory concentrations in the hundreds and 
thousands. This is in line with findings by Okba and colleagues17 
who also found a strong correlation between ELISA and neutraliza-
tion. Of note, the ELISA reagents used were derived from the origi-
nal sequence from Wuhan, the neutralization assays were performed 
with USA-WA1/2020 (an Asian-lineage strain) and the majority of 
sera were obtained from subjects infected with European-lineage 
viruses18. The observed correlation between ELISA and neutraliza-
tion assays hints at minimal antigenic changes.
We believe that our ELISA method will be very useful for sero-
surveys aimed at determining the real attack rate and infection 
fatality rate in different human populations, and to map the kinetics 
of the antibody response to SARS-CoV-2. While we found serocon-
version in severe, mild and asymptomatic cases, it is possible that 
some individuals do not seroconvert or that antibody titers wane 
within short periods of time. To be able to interpret serosurveys 
correctly, studies to assess the kinetics of the antibody response 
and the rate of non-responders are urgently needed. Clinical trials 
with convalescent serum as the therapeutic have been initiated in 
China (for example, NCT04264858). In addition, a recent report 
suggests that compassionate use of these interventions could be 
successful19. Screening potential plasma donors for high-antibody 
titers using our assay is faster and easier than performing standard 
neutralization assays in BSL3 containment laboratories. Our assay 
has already been implemented for this purpose in Mount Sinai’s 
Clinical Laboratory Improvement Amendments-regulated clinical 
laboratory and has received emergency use authorization from 
New York State and from the Food and Drug Administration. 
Indeed, more than 250 patients with COVID-19 have been compas-
sionately treated at Mount Sinai Hospital with antibody-rich plasma 
from convalescent donors identified with our assays (N. Bouvier, 
personal communication). Importantly, the assumption that anti-
bodies to SARS-CoV-2 confer protection from reinfection needs 
to be confirmed and studies to investigate antibody titer as a cor-
relate of protection should be started as soon as possible. We are 
making the methods and laboratory reagents widely available to 
the research community to support the global effort to limit and 
mitigate the spread of SARS-CoV-2.
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Methods
Recombinant proteins. The mammalian cell codon-optimized nucleotide 
sequence coding for the spike protein of the SARS-CoV-2 isolate (GenBank: 
MN908947.3) was synthesized commercially (Genewiz). The RBD (amino 
acids 319–541; RVQP…CVNF), along with the signal peptide (amino acids 
1–14; MFVF…VSSQ) plus a hexahistidine tag, was cloned into mammalian 
expression vector pCAGGS as well as in a modified pFastBac Dual vector for 
baculovirus system expression. The soluble version of the spike protein (amino 
acids 1–1,213; MFVF…IKWP), including a C-terminal thrombin cleavage site, 
T4 foldon trimerization domain and hexahistidine tag, was also cloned into 
pCAGGS. The protein sequence was modified to remove the polybasic cleavage 
site (RRAR to A), and two stabilizing mutations were introduced as well (K986P 
and V987P; wild-type numbering). Recombinant proteins were produced using 
the well-established baculovirus expression system and this system has been 
published in detail in refs. 20–22, including a video guide. Recombinant proteins 
were also produced in Expi293F cells (Thermo Fisher Scientific) by transfections 
of these cells with purified DNA using an ExpiFectamine 293 Transfection Kit 
(Thermo Fisher Scientific). Supernatants from transfected cells were harvested 
on day 3 post-transfection by centrifugation of the culture at 4,000g for 20 min. 
Supernatant was then incubated with 6 ml Ni-NTA Agarose (Qiagen) for 1–2 h at 
room temperature. Next, gravity flow columns were used to collect the Ni-NTA 
agarose and the protein was eluted. Each protein was concentrated in Amicon 
centrifugal units (EMD Millipore) and re-suspended in phosphate-buffered saline 
(PBS). Proteins were analyzed by reducing SDS-PAGE. The DNA sequence for all 
constructs is available from the Krammer Laboratory and has also been deposited 
in GenBank (additional information in the ‘Data availability’ statement). Several 
of the expression plasmids and proteins have also been submitted to the BEI 
Resources repository and can be requested from their web page for free (https://
www.beiresources.org/). S1 proteins of NL63 and 229E were obtained from Sino 
Biological (produced in hexahistidine-tagged 293HEK cells). A detailed protocol 
for protein expression of RBD and spike in mammalian cells is also available7.
SDS-PAGE. Recombinant proteins were analyzed via a standard SDS-PAGE 
gel to check protein integrity. Protein (1 µg) was mixed with 2× Laemmli buffer 
containing 5% β-mercaptoethanol at a ratio of 1:1. Samples were heated at 100 °C 
for 15 min and then loaded onto a polyacrylamide gel (5–20% gradient; Bio-Rad). 
Gels were stained with SimplyBlue SafeStain (Invitrogen) for 1–2 h and then 
de-stained in distilled water overnight.
Human samples. Human plasma and serum samples were obtained from a 
number of different sources.
First, de-identified samples from the University of Melbourne (n = 3; taken 
on days 2, 4 and 6 after symptom onset) and University of Helsinki (n = 1; taken 
on day 20 after symptom onset) (neutralizing titer: 1:160)6 were used as positive 
controls. For these, human experimental work was conducted according to the 
Declaration of Helsinki principles and according to the Australian National Health 
and Medical Research Council Code of Practice. All participants provided written 
informed consent before the study. The studies were approved by the Alfred 
Hospital (ID number 280/14) and University of Melbourne (ID numbers 1442952.1 
and 1955465.2) Human Research Ethics Committees, and under a research permit 
for project TYH2018322 of Helsinki University Hospital Laboratory.
Second, banked human samples were collected from study participants 
enrolled in several ongoing Institutional Review Board-approved longitudinal 
observational study protocols of the Mount Sinai Personalized Virology Initiative. 
The pre-pandemic serum panel comprised samples selected based on the 
date of collection (for example, autumn 2019) and whether participants had a 
documented history of viral infection (for example, dengue virus, hantavirus, 
Chikungunya virus or coronavirus NL63). All participants agreed to sample 
banking and future research use. Self-reported ethnicities of the individuals from 
whom samples were tested included Caucasian, Asian, African American and 
Hispanic. Samples included convalescent sera from a participant with an NL63 
infection, as determined by the BioFire Respiratory Panel. We included serum 
collected at day 3 post-symptom onset, as well as convalescent serum from the 
same person (day 30 post-symptom onset). These samples served as negative 
controls given that they were collected before SARS-CoV-2 spread in the United 
States. Six subjects were 20–29 years of age, 18 were 30–39 years of age, 13 were 
40–49 years of age, seven were 50–59 years of age and six were 60 years or older. 
For the mRBD ELISAs, sera from an additional nine subjects were tested (two aged 
30–39 years, four aged 40–49 years, two aged 50–59 years and one aged ≥60 years). 
The pre-pandemic panel was complemented by a panel of plasma samples 
collected between 2008 and 2011 from 50 individuals infected with human 
immunodeficiency virus 1.
Third, the Mount Sinai COVID-19 panel comprised serum (n = 12) and 
plasma samples from individuals with severe, mild or asymptomatic SARS-CoV-2 
infections (see Supplementary Table 1). Seven paired serum and plasma samples 
from patients with COVID-19 were used for comparison purposes. These 
samples were collected between 7 and 30 d post-symptom onset. These samples 
were collected from participants enrolled in an ongoing Institutional Review 
Board-approved study of the Mount Sinai Personalized Virology Initiative.
NHIG. The following NHIG preparations, each prepared from >1,000 blood or 
plasma donors and intended for intravenous use for medical conditions, were 
tested in an ELISA to determine whether they had reactivity against SARS-CoV-2 
spike or RBD: Octagam (M934A8541); Gamunex-c (B2GMD00943, A1GLD01882, 
B3GLD01223, A1GLD01902, B2GLD01972, B3GGD00143 and A1GKE00012 
(two different vials) and B2GKD00863 and B2GJE00033 (three different vials)); 
Gammagard Liquid (LE12T292AB, LE12V238AB and LE12V278AD); Gammagard 
S/D (LE08V027AB (four different vials)); and Gammagard Liquid (C19G080AAA, 
LE12V071AD, LE12V230AB, LE12V115AC, LE12V205AB, LE12VE25AB and 
LE12V115AC).
ELISA. The ELISA protocol was adapted from previously established protocols23,24. 
Overnight, 96-well plates (Immulon 4 HBX; Thermo Fisher Scientific) were 
coated at 4 °C with 50 µl per well of a 2 µg ml−1 solution of each respective protein 
suspended in PBS (Gibco). The next morning, the coating solution was removed 
and 100 µl per well of 3% non-fat milk prepared in PBS with 0.1% Tween 20 
(PBST) was added to the plates at room temperature for 1 h as a blocking solution. 
Serum samples were heated at 56 °C for 1 h before use to reduce the risk from 
any potential residual virus in the serum. Serial dilutions of serum and antibody 
samples were prepared in 1% non-fat milk prepared in PBST. The blocking 
solution was removed and 100 µl of each serial dilution was added to the plates for 
2 h at room temperature. Next, the plates were washed three times with 250 µl per 
well of 0.1% PBST. Next, a 1:3,000 dilution of goat anti-human IgG–horseradish 
peroxidase (HRP) conjugated secondary antibody (Thermo Fisher Scientific) was 
prepared in 0.1% PBST and 100 µl of this secondary antibody was added to each 
well for 1 h. Plates were again washed three times with 0.1% PBST. Once completely 
dry, 100 µl SIGMAFAST OPD (o-phenylenediamine dihydrochloride; Sigma–
Aldrich) solution was added to each well. This substrate was left on the plates for 
10 min and then the reaction was stopped by the addition of 50 μl per well of 3 M 
hydrochloric acid. The optical density at 490 nm (OD490) was measured using a 
Synergy 4 (BioTek) plate reader. The background value was set at an OD490 of 0.11 
and the AUC was calculated. AUC values below 1 were assigned a value of 0.5 for 
plotting and calculation purposes. Data were analyzed using Prism 7 (GraphPad). 
In some cases, end-point titers were calculated, with the end-point titer being the 
last dilution before reactivity dropped below an OD490 of <0.11. To determine the 
impact of heat treatments, paired samples that were heat treated or not treated were 
analyzed. NHIGs were run similar to serum and plasma samples but with a starting 
dilution at a concentration of 100 µg ml−1. Three non-SARS-CoV-2 reactive 
human monoclonal antibodies and CR3022 (refs. 12–14)—a human monoclonal 
antibody reactive to the RBD of both SARS-CoV-1 and SARS-CoV-2—were used 
as controls.
To assess the distribution of the different antibody isotypes and subclasses 
in the samples that reacted well in our standard ELISA, another ELISA was 
performed with different secondary antibodies25. These antibodies included 
anti-human IgA (α-chain-specific) HRP antibody (Sigma–Aldrich; A0295; 
1:3,000), anti-human IgM (μ-chain-specific) HRP antibody (Sigma–Aldrich; 
A6907; 1:3,000), anti-human IgG1 Fc-HRP (Southern Biotech; 9054-05; 1:3,000), 
anti-human IgG2 Fc-HRP (Southern Biotech; 9060-05; 1:3,000), anti-human IgG3 
hinge-HRP (Southern Biotech; 9210-05; 1:3,000) and anti-human IgG4 Fc-HRP 
(Southern Biotech; 9200-05; 1:3,000).
Of note, different ELISA substrates and stopping solutions that are less 
hazardous may be used in order to comply to local guidelines if appropriate.
Microneutralization assay. Vero E6 cells were seeded at a density of 20,000 cells 
per well in a 96-well cell culture plate in complete Dulbecco’s Modified Eagle 
Medium (cDMEM). The following day, heat-inactivated serum samples (dilution 
of 1:10) were serially diluted threefold in 1× MEM (10% 10× minimal essential 
medium (Gibco), 2 mM l-glutamine, 0.1% sodium bicarbonate (wt/vol; Gibco), 
10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Gibco), 
100 U ml–1 penicillin, 100  ug/ml–1 streptomycin (Gibco) and 0.2% bovine serum 
albumin (MP Biomedicals)). The authentic SARS-CoV-2 virus (USA-WA1/2020; 
GenBank: MT020880) was diluted to a concentration of 100 TCID50 (50% tissue 
culture infectious dose) in 1× MEM. Then, 80 μl of each serum dilution and 80 μl 
of the virus dilution were added to a 96-well cell culture plate and allowed to 
incubate for 1 h at room temperature. cDMEM was removed from Vero E6 cells 
and 120 μl of the virus–serum mixture was added to the cells. Then, the cells were 
incubated at 37 °C for 1 h. After the 1-h incubation, the virus–serum mixture 
was removed from the cells and 100 μl of each corresponding serum dilution 
and 100 μl of 1× MEM containing 1% FBS (Corning) was added to the cells. The 
cells were incubated for 48 h at 37 °C and then fixed with 10% paraformaldehyde 
(Polysciences) for 24 h at 4 °C. Following fixation, the paraformaldehyde 
was removed and the cells were washed with 200 μl PBS. The cells were then 
permeabilized by the addition of 150 μl PBS containing 0.1% Triton X-100 for 
15 min at room temperature. The plates were then washed three times with PBS 
containing PBST and blocked in blocking solution (3% milk (American Bio) in 
PBST) for 1 h at room temperature. After blocking, 100 μl of mAb 1C7 (anti-SARS 
nucleoprotein antibody generated in house) at a dilution of 1:1,000 was added 
to all wells and the plates were allowed to incubate for 1 h at room temperature. 
The plates were then washed three times with PBST before the addition of goat 
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anti-mouse IgG–HRP (Rockland Immunochemicals), diluted 1:3,000 in blocking 
solution for 1 h at room temperature. Plates were then washed three times with 
PBST, and SIGMAFAST OPD (Sigma–Aldrich) was added. After a 10-min 
incubation at room temperature, the reaction was stopped by adding 50 μl 3 M 
hydrochloric acid to the mixture. The OD490 was measured on a Synergy 4 plate 
reader (BioTek). A cut-off value of the average of the optical density values of blank 
wells plus three standard deviations was established for each plate and used to 
calculate the microneutralization titer. Microneutralization assays were performed 
in a facility with a biosafety level of 3.
Statistical analysis. Differences between negative controls and positive controls 
were analyzed using an unpaired t-test. Differences between paired non-treated 
and heat-treated samples, as well as paired serum and plasma samples, were 
analyzed using a paired t-test. Correlations between ELISA titers and neutralization 
titers were analyzed using Spearman’s rank test. Analyses were performed with 
GraphPad Prism.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The data shown in the manuscript are available upon request from the 
corresponding author. Nucleotide sequences of both constructs have been 
submitted to NCBI (GenBank IDs MT380724.1 and MT380725.1). Expression 
plasmids have been deposited to BEI Resources (https://www.beiresources.org/), 
and plasmids and sequences are also available from the corresponding author.  
A detailed protocol for expression and ELISA setup has been published  
(https://currentprotocols.onlinelibrary.wiley.com/doi/full/10.1002/cpmc.100).
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Extended Data Fig. 1 | Constructs for recombinant protein expression. a, Visualization of the trimeric spike protein of SARS-CoV-2 based on PBD # 6VXX 
using Pymol3. One monomer is colored in dark blue while the remaining two monomers are held in light blue. The receptor binding domain (RBD) of the 
dark blue trimer is highlighted in red. b, Schematic of the wild type full length spike protein with signal peptide, ectodomain, receptor binding domain, furin 
cleavage site, S1, S2, and transmembrane and endodomain domain indicated. c, Schematic of the soluble trimeric spike. The polybasic/furin cleavage site 
(RRAR) was replaced by a single A. The transmembrane and endodomain were replaced by a furin cleavage site, a T4 foldon tetramerization domain and 
a hexahistidine tag. Introduction of K986P and V987P has been shown to stabilize the trimer in the pre-fusion conformation. d, Schematic of the soluble 
receptor binding domain construct. All constructs are to scale. e Reducing SDS PAGE of insect cell and mammalian cell derived soluble trimerized spike 
protein (iSpike and mSpike). f Reducing SDS PAGE of insect cell derived and mammalian cell derived recombinant receptor binding domain (iRBD and 
mRBD). Experiments were performed six times with the same result.
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Extended Data Fig. 2 | Human normal immunoglobulin preparations and historic sera from HiV + patients do not react with the SAR-CoV-2 spike.  
a, b, Reactivity of 21 different pools of human normal immunoglobulin (HNIG) preparations (27 different vials) to mRBD and mSpike of SARS-CoV-2. 
MAb CR3022 was used as positive control, three different irrelevant human mAbs were used as negative control. c, d shows reactivity of historic 
samples from 50 HIV + individuals to mRBD and mSpike of SARS-CoV-2. Both HNIG and serum samples from HIV + donors were collected before the 
SARS-CoV-2 pandemic. Experiments were performed once. MAb CR3022 was used as positive control at a starting concentration of 100 ug/ml. Of note, 
the experiments in A and C as well as B and D were done at the same time and their positive controls are shared and displayed in both panels. Experiments 
were performed once.
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Extended Data Fig. 3 | isotypes and subtypes of antibodies from COViD19 patients to the soluble spike protein and microneutralization titers.  
a, Mammalian cell derived spike protein was used to study isotype/subclass distribution of antibodies (n = 13 positive samples). Lines represent the 
geometric mean. b, Microneutralization assay (n = 12) performed with authentic SARS-CoV-2. Lines represent curves fitted using an inhibitor (log) versus 
response variable slope with four parameters function in Graphpad Prism. Experiments were performed once.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size Sample size was determined/limited by available number of samples. The maximum number of samples available was analyzed. Positive and 
negative control samples for assay development showed a clear difference in reactivity that could already be detected with an n of 4 positive 
samples.
Data exclusions All data was included in the analysis
Replication Assays were repeated with 4 different substrates. ELISAs for each substrate were run once each. All attempts at replication were successful.
Randomization Randomization was not performed since the purpose of this work was assay development.
Blinding Blinding was not performed since the purpose of this work was assays development. Performance tests of this assay setup in our clinical 
laboratory have been conducted using blinded operators.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems













Antibodies used mAb CR3022 is a published antibody with known reactivity to the RBD of SARS-CoV-1 and 2. 1C7 is an unpublished in-house mAb 
with reactivity to the N protein of SARS-CoV-1 and 2.
Validation Both mAbs were validated by binding studies to cells infected with SARS-CoV-2.
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) Sf9, High Five and and Vero.E6 cells were sourced from ATCC. Expi293F cells were sourced from ThermoFisher.
Authentication No authentication was performed. All expression constructs were Sanger sequenced.
Mycoplasma contamination The cell lines were not tested for mycoplasma.
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified cell lines were used.
Human research participants
Policy information about studies involving human research participants
Population characteristics Only de-identified samples were used. This is considered non-human subject research. 16 samples were from COVID19 survivors, 
109 negative control samples were from a non-COVID19 infected cohort age 20 to 65+.
Recruitment No participants were enrolled. All samples were preexisting.
Ethics oversight Alfred Hospital (ID #280/14) and University of Melbourne (ID #1442952.1, 1955465.2) Human Research Ethics Committees,  
under research permit for project TYH2018322 of Helsinki University Hospital Laboratory and by the IRB of the Icahn School of 
Medicine at Mount Sinai, NY
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